Y&R Lands Aventis Drug

NEW YORK — An integrated approach led to Young & Rubicam’s successful pitch for Lovenoz, an Aventis drug that treats deep-vein thrombosis. Y&R’s New York office will handle creative duties on the estimated $15 million account, while Mediaedge:cia, here, will handle media chores and Burson-Marsteller, also here, will work on public relations. WPP Group’s Y&R and its sister shops landed the business after a review that involved other undisclosed shops from rival holding companies Omnicom Group and Interpublic Group.